German construction sector still in recession, civil engineering only bright spot
Daniel Rabinowitz, Secretary and Chief Legal Officer at Natera, Inc. (NASDAQ:NTRA), sold 1,364 shares of common stock on September 30, 2025, at a price of $162.0528, totaling approximately $221,040. The sale occurred near the stock’s current trading level of $161.61, with Natera showing strong momentum with a 23% return over the past year. InvestingPro analysis indicates the stock is fairly valued, with 11 analysts recently revising earnings estimates upward.
On September 29, 2025, Rabinowitz also exercised options on 2,500 shares of Natera’s common stock. These shares were acquired through the vesting of restricted stock units. The company, currently valued at $22.18 billion, has demonstrated impressive revenue growth of 44% in the last twelve months. Get deeper insights into Natera’s valuation metrics and 8 additional exclusive ProTips with InvestingPro.
In other recent news, Natera, Inc. has made significant strides in its clinical trials and testing capabilities. The company announced the enrollment of over 1,600 patients in the EXPAND clinical trial for its Fetal Focus prenatal test, aiming to confirm test results through prenatal or postnatal diagnostic testing. Additionally, Natera revealed promising findings from its study on circulating tumor DNA (ctDNA) in testicular cancer, where the Signatera test outperformed standard tumor markers in predicting patient outcomes. Another study highlighted the efficacy of the Signatera test for monitoring recurrence and treatment response in early-stage uterine cancer patients.
On the financial front, Wells Fargo resumed coverage of Natera with an Equal Weight rating, citing the company’s strong position in cell-free DNA testing technology. Piper Sandler reiterated an Overweight rating for Natera, following positive results from the IMvigor011 trial, which demonstrated that MRD-negative status is linked to improved overall survival. These developments underscore Natera’s ongoing efforts to advance its testing capabilities across various medical fields.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.